Lundbeck
Lundbeck buys Chelsea Therapeutics
May 12, 2014Research and Development, Sales and Marketing Chelsea Therapeutics, Lundbeck
Lundbeck could pay as much as $658 million for neurological disorder specialist Chelsea Therapeutics as the firm looks to shore …
Lundbeck teams up with Lieber Institute
April 3, 2014Research and Development, Sales and Marketing Astellas, AstraZeneca, Lundbeck, Pfizer, Roche, ability, brain, lieber, lilly
Lundbeck has entered into a new partnership with the Lieber Institute for Brain Development in the hope of discovering new …
Danish government: ‘Sue pharma firms’
January 23, 2014Sales and Marketing Actavis, Danish, Denmark, Lundbeck, celexa
A senior figure in Denmark’s government has said that local authorities should take legal action against pharma firms which put …
Positive CHMP verdicts for Actelion and Lundbeck
October 28, 2013Sales and Marketing Actelion, CHMP, FDA, Lundbeck
Actelion and Lundbeck both took a step closer to EU approval for two drugs seen as pivotal to their future …
Brintellix ‘yes’ from FDA
October 4, 2013Sales and Marketing FDA, Lundbeck, Takeda, brintellix
Takeda Pharmaceutical Company and Lundbeck are celebrating after the FDA approved their depression treatment Brintellix – despite there being no …
Otsuka buys Astex for $866 million
September 6, 2013Sales and Marketing Astex, Lundbeck, Onyx, Otsuka
Otsuka Pharmaceutical is to buy UK-based Astex Pharmaceuticals in a deal that will see the Tokyo-based firm shelling out $866 …
Lundbeck appealing against European fine
September 2, 2013Sales and Marketing EMA, Lundbeck, pay for delay
Lundbeck is fighting a ruling by European authorities that could see it fined nearly €100 million over a pay-for-delay deal. …
Lundbeck/Otsuka Alzheimer’s drug improves cognition
July 17, 2013Research and Development, Sales and Marketing Alzheimer's, Lundbeck, Otsuka
Lundbeck and partner Otsuka have posted positive Phase II results for their experimental Alzheimer’s drug. The latest data show statistically …
Lundbeck cuts more jobs in Europe
June 24, 2013Manufacturing and Production, Research and Development, Sales and Marketing Lexapro, Lundbeck, cuts
Lundbeck is to cut yet more jobs in Europe as the Danish pharma firm restructures its operations to focus on …
Nine fined in EU pay-for-delay deals
June 20, 2013Manufacturing and Production, Sales and Marketing EU, Lundbeck, Merck, Ranbaxy
Nine pharma firms have been handed hefty fines by the European Commission over allegations that they willingly blocked generic versions …
Promise for Lundbeck and Takeda’s depression drug
May 20, 2013Research and Development, Sales and Marketing Lexapro, Lundbeck, Takeda, cymbalta, depression, lilly
Takeda and Lundbeck’s treatment for major depressive disorder has demonstrated a significant improvement in patients’ symptoms during trials. Brintellix (Vortioxetine) …
Lundbeck moves ahead in Q1
May 3, 2013Sales and Marketing Lexapro, Lundbeck, Otsuka, Q1
Lundbeck’s sales and profit increase in the first three months of 2013 was due largely to one-off payments it received, …
Lundbeck booze pill for EU
March 1, 2013Sales and Marketing Lundbeck, alcohol, selincro
Lundbeck’s novel pill Selincro has been given European marketing authorisation to help patients with a drink problem to cut down. …
Lundbeck elects new chairman
February 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lundbeck
Lundbeck has announced it will be electing Håkan Björklund as its new chairman as Mats Pettersson steps down. Pettersson, a …
Lexapro US loss hits Lundbeck
February 7, 2013Sales and Marketing Danish, Lexapro, Lundbeck
The loss of US patent protection on antidepressant Lexapro has put a significant dent in Lundbeck’s financial performance for 2012. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
